Revolution Medicines Prices $2.0 Billion Offering, Upsizing Capital Raise for Pipeline Development

summarizeSummary

Revolution Medicines finalized the pricing for its upsized $2.0 billion concurrent public offering of common stock and convertible notes, securing substantial capital for its pipeline following positive clinical trial results.

check_boxKey Events

• Offering Priced and Upsized

  Revolution Medicines finalized pricing for a concurrent offering of 10,563,381 shares of common stock at $142.00 per share and $500 million in 0.50% convertible senior notes due 2033. This significantly increases the total capital raise from the previously announced $1 billion to approximately $2.0 billion (or up to $2.225 billion if underwriters exercise their option).

• Substantial Capital Infusion

  The combined offerings are expected to generate net proceeds of approximately $1.92 billion (or $2.137 billion with full option exercise), providing significant funding for general corporate purposes, including research and development, potential commercialization, and strategic investments.

• Favorable Pricing Terms

  The common stock offering is priced at a modest discount of approximately 3.4% to the last reported sale price, while the convertible notes feature a 40% conversion premium, indicating strong market demand and investor confidence.

• Strategic Timing

  This substantial capital raise follows highly positive late-stage clinical trial results announced on April 13, 2026, and occurs while the company's stock is trading near its 52-week high, allowing the company to capitalize on a strong valuation.

auto_awesomeAnalysis

This Free Writing Prospectus (FWP) finalizes the terms and pricing of Revolution Medicines' concurrent public offerings, significantly increasing the total capital raise to approximately $2.0 billion. The offering, comprising common stock and convertible senior notes, is priced at a modest discount to the market for the common stock and includes a favorable 40% conversion premium for the notes. This substantial capital infusion provides significant financial runway for general corporate purposes, including critical research and development, potential commercialization of product candidates, and strategic acquisitions. The successful upsized offering, coming shortly after highly positive late-stage clinical trial results announced on April 13, 2026, and while the stock trades near its 52-week high, demonstrates strong investor confidence and strengthens the company's ability to advance its oncology pipeline.